Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in locally advanced esophageal squamous cell carcinoma
NCT05495152Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Started Aug 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05495152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495152.